ESC 2019 | CLARIFY: Symptoms Predict Risk Only in Patients with Prior MI

The 5-year follow up of patients with chronic stable angina (or as the guidelines currently call it “chronic coronary syndrome”) indicate the risk of cardiovascular death or non-fatal MI is quite low, but risk factor control is still fairly poor. This information comes from the CLARIFY study, presented at ESC 2019 and published simultaneously in Eur Heart J.

ESC 2019 | CLARIFY: Los síntomas predicen riesgo solamente en pacientes con infarto previo

In the general population of symptomatic patients, no association was found between angina and events, but the presence of new symptoms in patients with a history of MI significantly increased the risk of a second MI or cardiovascular death.

It seems obvious to conclude that patients with a history of MI are at higher risk, but what this study brings to the table is that even when all test outcomes result normal (ECG, SPECT, etc.) these are still high-risk patients.

The CLARIFY is aligned with the new guidelines and alerts us about the risk these patients present, saying they are not as stable as they seem.


Read also: ESC 2019 | Pure: Body Mass Index Shows Low Correlation with Cardiovascular Events.


This study enrolled 32703 patients from 45 countries with coronary artery disease considered “stable”, with symptomatic myocardial ischemia or angiographic stenosis >50%. The protocol allowed the inclusion of patients with prior MI or revascularization, as long as the event had taken place over three months earlier.

More than 95% of the population was on some antiplatelet antiaggregant, more than 80% were on statins, beta-blockers and inhibitors of the conversion enzyme/angiotensin blockers.

This seems a delicate treatment of guideline-oriented goals. However, risk factor management was poor.

Only 65% reached the conventional target of 140/90 mmHg blood pressure, only 61% reached <100 mg/dl LDL and only 42% managed to control both factors simultaneously.


Read also: ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries.


If we use the threshold values recommended by the guidelines, it all gets slightly worse, seeing as just 7.4% of the population reach these targets.

After 5 years, 8% of the population presented the primary end point (cardiovascular death or non-fatal MI), that is 1.7 events rate per 100 persons/year.

Original title: Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.

Reference: Sorbets E et al. Eur Heart J. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...